Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TOMZ | PRESS-RELEASE | bullish | 6/10 | TOMI Environmental Solutions highlighted strong engagement at INTERPHEX 2026, reporting over 200 interactions with curre | Apr 27, 2026 |
| TERN | PRESS-RELEASE | bullish | 8/10 | Terns Pharmaceuticals announced FDA Breakthrough Therapy Designation for TERN-701, an oral BCR::ABL1 inhibitor, in chron | Apr 27, 2026 |
| EVAX | PRESS-RELEASE | neutral | 3/10 | Evaxion promoted its Chief Scientific Officer, Birgitte Rønø, to also serve as Chief Operating Officer to enhance extern | Apr 27, 2026 |
| ALLR | PRESS-RELEASE | bullish | 7/10 | Allarity Therapeutics announced a Notice of Allowance from the USPTO for a patent covering its DRP® companion diagnostic | Apr 27, 2026 |
| IOVA | PRESS-RELEASE | neutral | 1/10 | Iovance Biotherapeutics, Inc. announced it will report its Q1 2026 results on May 7, 2026. | Apr 27, 2026 |
| ARDX | PRESS-RELEASE | neutral | 3/10 | Ardelyx announced that data on the long-term effects of XPHOZAH (tenapanor) on serum electrolytes and nutrition biomarke | Apr 27, 2026 |
| APLM | PRESS-RELEASE | bullish | 7/10 | Apollomics reported its 2025 full-year financial results, posting $8.5M in revenue from a licensing deal with LaunXP, a | Apr 27, 2026 |
| BIVI | PRESS-RELEASE | neutral | 3/10 | BioVie announced a virtual KOL event on May 7, 2026, featuring Dr. Suzanne de la Monte to discuss the mechanism of actio | Apr 27, 2026 |
| CRMD | PRESS-RELEASE | bullish | 8/10 | CorMedix announced positive Phase III topline results from the ReSPECT trial, showing that rezafungin met the primary en | Apr 27, 2026 |
| CMPX | PRESS-RELEASE | bullish | 8/10 | Compass Therapeutics announced that tovecimig, in combination with paclitaxel, achieved a highly statistically significa | Apr 27, 2026 |
| ATHE | PRESS-RELEASE | bullish | 7/10 | Alterity Therapeutics received positive FDA feedback on the chemistry, manufacturing, and control (CMC) aspects of its A | Apr 27, 2026 |
| SION | PRESS-RELEASE | mixed | 6/10 | Sionna Therapeutics announced completion of patient enrollment in its Phase 2a PreciSION CF trial evaluating SION-719, a | Apr 27, 2026 |
| FULC | PRESS-RELEASE | neutral | 4/10 | Fulcrum Therapeutics reported Q1 2026 net loss of $18.9M ($0.25 per share), slightly narrower than the consensus estimat | Apr 27, 2026 |
| ETON | PRESS-RELEASE | mixed | 5/10 | Eton Pharmaceuticals has dosed the first patient in a pilot clinical study evaluating ET-700, its extended-release zinc | Apr 27, 2026 |
| RLAY | PRESS-RELEASE | bullish | 8/10 | Relay Therapeutics announced plans to advance its zovegalisib + atirmociclib + endocrine therapy triplet into a Phase 3 | Apr 27, 2026 |
| ATAI | PRESS-RELEASE | neutral | 3/10 | AtaiBeckley Inc. received the Silver Award in OVID Health’s 2026 Patient Participant Index for its collaboration with th | Apr 27, 2026 |
| CMPX | PRESS-RELEASE | neutral | 5/10 | Compass Therapeutics (CMPX) will host a webcast on April 27, 2026, to present topline secondary endpoint data from its P | Apr 24, 2026 |
| ANAB | PRESS-RELEASE | bullish | 7/10 | AnaptysBio announced a favorable court ruling in its ongoing litigation with Tesaro/GSK, with the Delaware Chancery Cour | Apr 24, 2026 |
| INDV | PRESS-RELEASE | bullish | 7/10 | Indivior presented new real-world evidence at the ASAM Conference showing that its long-acting buprenorphine therapy SUB | Apr 24, 2026 |
| ALVO | PRESS-RELEASE | neutral | 2/10 | Alvotech announced it will release its Q1 2026 financial results on May 6, 2026, followed by a webcast and live Q&A on M | Apr 24, 2026 |
| ALVO | PRESS-RELEASE | neutral | 1/10 | Alvotech announced it will report its Q1 2026 results on May 6, 2026. | Apr 24, 2026 |
| SNDX | PRESS-RELEASE | neutral | 1/10 | Syndax Pharmaceuticals, Inc. announced it will report its Q1 2026 results on April 30, 2026. | Apr 24, 2026 |
| ANIP | PRESS-RELEASE | neutral | 1/10 | ANI Pharmaceuticals, Inc. announced it will report its Q1 2026 results on May 8, 2026. | Apr 24, 2026 |
| CATX | PRESS-RELEASE | neutral | 3/10 | Perspective Therapeutics announced upcoming corporate updates in May 2026, including an analyst event, first-quarter fin | Apr 24, 2026 |
| OTLK | PRESS-RELEASE | bearish | 6/10 | Outlook Therapeutics raised approximately $5.0 million through a registered direct offering of 16.1 million shares at $0 | Apr 23, 2026 |
| ABSI | PRESS-RELEASE | neutral | 1/10 | Absci Corporation announced it will report its Q1 2026 results on May 7, 2026. | Apr 23, 2026 |
| NATR | PRESS-RELEASE | neutral | 1/10 | Nature's Sunshine Products, Inc. announced it will host a conference call on May 7, 2026 to discuss its Q1 2026 results. | Apr 23, 2026 |
| LONA | PRESS-RELEASE | bullish | 7/10 | LeonaBio announced a virtual Key Opinion Leader event featuring two prominent breast cancer experts to discuss the poten | Apr 23, 2026 |
| KNSA | PRESS-RELEASE | neutral | 1/10 | Kiniksa Pharmaceuticals International, Plc announced it will report its Q1 2026 results on April 28, 2026. | Apr 23, 2026 |
| VCEL | PRESS-RELEASE | neutral | 1/10 | Vericel Corporation announced it will report its Q1 2026 results on May 7, 2026. | Apr 23, 2026 |